The Validation Pathways for "Mildness": Compliance Boundaries of Eye Irritation, Skin Patch, and Repeat Use Testing

I. "Mildness" Must Be Proven, Not Just Claimed

If the evolution of cosmetic efficacy claims over the past decade has moved from "emotional language" to "ingredient science," the next trend is moving from "ingredient science" to "test data-driven substantiation."

For makeup removers—a category that involves direct contact with the periorbital and facial skin and is used at high frequency every day—the validation pathways required for "mildness" claims are more complex and stringent than almost any other category. Behind every phrase like "non-irritating," "ophthalmologist tested," "dermatologist tested," or "hypoallergenic formula," there lies a specific set of testing methodologies, subject scale requirements, and compliance criteria.

This article will systematically deconstruct the three core validation pathways for makeup remover mildness: eye irritation testing, skin patch testing (including HRIPT), and repeat-use tolerance testing tailored to makeup removal scenarios, clarifying the compliance status and applicable boundaries of each testing method in major global markets.

II. Pathway 1: Eye Irritation Validation

Regulatory Background: System Reconstruction Post-Animal Testing Ban

Makeup removers inevitably contact the eye area, making ocular safety validation a rigid requirement for this category. In the EU, animal testing for cosmetics has been completely banned, and safety assessments rely entirely on validated non-animal methods and SCCS (Scientific Committee on Consumer Safety) guidelines. The HET-CAM test represents a relevant alternative method for evaluating the irritation potential of such products, showing good correlation with in vivo Draize test data, which remains the only method formally recognized by the OECD (OECD TG 405).

Currently, the alternative testing system for eye irritation accepted by international regulatory agencies and the industry has formed a "Tiered Approach" framework. Core methods include:

Method Full Name	OECD No.	Primary Use
BCOP (Bovine Corneal Opacity and Permeability)	TG 437	Identifying substances causing serious eye damage.
ICE (Isolated Chicken Eye)	TG 438	Categorizing serious eye damage / eye irritation.
FL (Fluorescein Leakage)	TG 460	Screening for moderate irritants.
RhCE (Reconstructed human Cornea-like Epithelium)	TG 492	Grading non-serious irritants.
HET-CAM (Hen's Egg Test-Chorioallantoic Membrane)	—	Comprehensive assessment of cosmetic eye irritation.

Validation in vivo and in vitro correlation analyses show that current strategies rely on an integrated approach combining multiple analytical methods to gain regulatory confidence. Each method has its advantages and limitations; no single method can completely replace the Draize test for all product types.

Ophthalmological Test: The Necessary Pathway for "Ophthalmologist Tested" Claims

For the highest-value eye safety claims in makeup removers—"Ophthalmologist Tested" and "Suitable for Contact Lens Wearers"—human use tests must be completed under in vivo clinical conditions supervised by an ophthalmologist.

Standard ophthalmological tolerance indirect instillation tests recruit healthy male and female subjects, at least 50% of whom are contact lens wearers. An ophthalmologist evaluates the study on-site, using a slit lamp to ensure the product does not cause irritation. In direct instillation tests, the product is diluted and dropped directly into the eyes via a dropper, and scores are compared to baseline to determine redness/swelling levels. These studies support claims like "Ophthalmologist Tested/Approved" and "Suitable for Contact Lens Wearers."

III. Pathway 2: Skin Patch Testing System

2.1 Single Patch Test (24h Closed Patch Test)

This is the most basic skin local tolerance test, suitable for confirming that the formula does not produce primary irritation after a single use. Standard Operating Procedure: The product is applied to a closed patch (Finn Chamber or T.R.U.E. Test patch) and placed on the subject's upper back or inner arm for 24–48 hours before removal. Skin reactions are read at 30 minutes and 24 hours post-removal. Reactions are graded on a 0–4 (or 0–3) scale, where 0 = no reaction, and 3 or 4 = strong positive reaction. Single patch tests typically require 20–30 subjects and serve as the first step in basic skin safety assessment, but they do not support claims like "non-sensitizing" or "hypoallergenic."

2.2 Human Repeat Insult Patch Test (HRIPT): The Core Evidence for Mildness Claims

The Human Repeat Insult Patch Test (HRIPT) is currently the industry-recognized gold standard for comprehensive validation of skin irritation and contact sensitization.

HRIPT represents the gold standard for evaluating the safety and sensitization potential of skincare products. It simulates real-world usage patterns by repeatedly applying the product to volunteers over several weeks. The evaluation includes three phases: Induction Phase (repeated application), Rest Phase, and Challenge Phase. Skin reactions are monitored throughout to assess whether the product triggers an allergic response after initial contact.

HRIPT takes about 6 weeks to complete, divided into three stages:

1. Induction Phase: The test substance is repeatedly applied to the same skin area (usually the upper back) over 2–3 weeks, with each patch maintained for 48–72 hours.

2. Rest Phase: Application stops for about 2 weeks to allow the skin to recover.

3. Challenge Phase: The product is reapplied to a new, naive skin site to evaluate delayed-type hypersensitivity (allergic contact dermatitis). This method is widely accepted by the US FDA as an appropriate methodology for evaluating the sensitization potential of topical products.

In the US, the FDA does not define or mandate the specific meaning of terms like "Hypoallergenic" or "Dermatologist Tested," meaning the burden of substantiation falls entirely on the brand. To make these claims credible, documented clinical or dermatological evaluations are required. Common testing protocols include RIPT, HRIPT (a more rigorous version with controlled induction and challenge phases), and Dermatologist Evaluation Panels.

IV. Pathway 3: Repeat Use Tolerance Testing (Cumulative Irritation Test, CIT)

Why Do Makeup Removers Need Specific Repeat Use Testing?

Single patch tests and HRIPT evaluate "whether the product sensitizes under intensified conditions," but there is a crucial difference between this and the actual usage scenario of makeup removers: consumers use the product 1–2 times daily, applying it to facial skin via cotton pad friction. This superposition of low dose + high frequency + mechanical friction may produce cumulative irritation effects that single tests cannot capture.

The Cumulative Irritation Test (CIT) is specifically designed for this. Its operational logic is: apply the product to the inner arm of subjects daily for 14–21 days, observe and score skin irritation daily, and calculate the Cumulative Irritation Index (CII). The lower the CII, the lower the cumulative irritation risk, directly supporting claims like "gentle for daily use" or "safe for repeated use."

Key Differences Between CIT and HRIPT:

Dimension	HRIPT	CIT
Primary Purpose	Evaluate contact sensitization potential	Evaluate cumulative irritation potential
Test Duration	Approx. 6 weeks	2–3 weeks
Subject Scale	50–100 people	20–30 people
Risk Type Covered	Type IV allergic reaction (delayed hypersensitivity)	Primary cumulative irritation (non-immunological)
Supported Claims	Hypoallergenic / Dermatologist Tested / Non-sensitizing	Gentle for daily use / Safe for repeated use

For daily-use makeup removers, a CIT + HRIPT combination is recommended to comprehensively cover both the "safe for repeated use" and "hypoallergenic" claim dimensions.

Conclusion: Testing Pathways Determine Claim Boundaries, Which Determine Market Competitiveness

Although compliant with local regulations, some cosmetics (including children's products) still show irritation reactions in HET-CAM tests. This finding highlights the importance of supplementing skin assessment with eye irritation analysis, especially for products that may come into contact with the eyes.

The core logic here is: meeting the minimum regulatory requirements does not equal the product is truly mild. What truly wins the trust of professional buyers in the international market are the brands and suppliers who proactively build a complete testing evidence chain.

Are you looking for a reliable Skincare factory?

Are you seeking a trusted partner to launch or scale your skin care line? At Deva Skincare,we specialize in developing safe formulations that combine barrier science with clean, compliant manufacturing.

Our R&D team and certified production facilities deliver turnkey OEM/ODM solutions tailored to your target market’s regulatory and consumer expectations.

By collaborating with Deva Skincare, you gain access to industry-leading expertise and innovative formulations that set your brand apart in the competitive global market. Contact us today to discover how we can help you succeed.